- Preparation method of indacaterol intermediate 5-chloracetyl-8-benzyloxy-2(1H)-quinolinone
-
The invention discloses a preparation method of an indacaterol intermediate 5-chloracetyl-8-benzyloxy-2(1H)-quinolinone. The method includes: taking o-methoxyaniline, cinnamoyl chloride, aluminium trichloride, trifluoromethanesulfonic acid, chloroacetyl chloride, and benzyl bromide as the raw materials, and carrying out four-step reaction, i.e. amidation reaction, ring closing reaction, Friedel-Crafts reaction, and hydroxylation reaction. The preparation method provided by the invention has the advantages of high yield, low cost, few three waste, easy operation and safety, and is suitable forindustrialization.
- -
-
Paragraph 0023; 0024
(2018/04/02)
-
- COMPOUND HAVING β2 ADRENALINE RECEPTOR AGONIST ACTIVITY AND METHOD FOR PRODUCING INTERMEDIATE THEREOF, AND COMPOUND THEREOF
-
PROBLEM TO BE SOLVED: To provide a compound which has a β2 adrenaline receptor (adrenoreceptor) agonist activity and a new efficient method for producing the compound. SOLUTION: There is provided: a new method for producing a compound, which is represented by the formula (III) as a pharmaceutical and has adrenoreceptor agonist activity, via a compound represented by the formula (II) from a compound represented by the formula (I); and the compound. (X is a leaving group or an amino group which is substituted with one H or an alkyl group R1 and one H or a protective group P2 of an amino group.) COPYRIGHT: (C)2015,JPOandINPIT
- -
-
Paragraph 0120; 0121
(2017/01/02)
-
- HYDROXY-SUBSTITUTED BENZO-CONDENSED HETEROCYCLES FOR USE AS BETA AGONISTS IN THE TREATMENT OF RESPIRATORY DISEASES
-
The invention relates to the compounds of general formula (1), wherein the groups n, A, B, R1, R2 and R3 are defined as in the claims and in the description, and to methods for producing the same. The invention also relates to the use of these compounds as drugs, especially as drugs for use in the treatment of respiratory diseases.
- -
-
Page/Page column 25
(2010/02/14)
-
- Beta agonists for the treatment of respiratory diseases
-
The present invention relates to compounds of general formula 1 wherein the groups n, A, B, R1, R2 and R3 may have the meanings given in the claims and in the specification, processes for preparing them, and their use as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.
- -
-
Page/Page column 10
(2010/02/15)
-
- ORGANIC COMPOUNDS
-
A process for preparing 8-substituted oxy-5-((R)-2-halo-l-hydroxy-ethyl)-(1 H)-quinolin-2-ones or acceptable solvates thereof. The process involves reacting a 5-(α-haloacetyl)-8-substituted oxy-(1H)-quinolin-2-one with a reducing agent in the presence of a chiral agent and a base to form a 8-(substituted oxy)-5-((R)-2-halo-l-hydroxy-ethyl)-(1H)-quinolin-2-one, said chiral agent having a formula (I) or (II), wherein M, L, X, R1, R2 and R3 have the meanings as indicated in the specification.
- -
-
Page/Page column 34-35
(2008/06/13)
-
- A PROCESS FOR THE PREPARATION OF 5-(HALOACETYL)-8-(SUBSTITUTED OXY)-(1H)-QUINOLIN-2-ONES
-
The invention relates to a process for preparing 5-(α-haloacetyl)-8-substituted oxy-(1H)-quinolin-2-ones. The process involves (i) reacting (a) 8-hydroxy-(1H)-quinolin-2-one with an acylating agent and a Lewis acid to form 5-acetyl-8-hydroxy-(1H)-quinolin-2-one; or (b) 8-hydroxy-(lH)-quinolin-2-one with an acylating agent to form 8-acetoxy-(lH)-quinolin-2-one, and treating, in-situ, the 8-acetoxy-(1H)-quinolin-2-one with a Lewis acid to form 5-acetyl-8-hydroxy-(1H)-quinolin-2-one; or (c) 8-acetoxy-(1H)-quinolin-2-one with a Lewis acid to form 5-acetyl-8-hydroxy-(lH)-quinolin-2-one; (ii) reacting the 5-acetyl-8-hydroxy-(1H)-quinolin-2-one prepared in Step (i) with a compound having the Formula RL in the presence of a base and a solvent to form 5-acetyl-8-substituted oxy-(1H)-quinolin-2-one, wherein R is a protecting group and L is a leaving group; and (iii) reacting the 5-acetyl-8-substituted oxy-(1H)-quinolin-2-one with a halogenating agent in the presence of a solvent to form a 5-(α-haloacetyl)-8-substituted oxy-(1H)-quinolin-2-one.
- -
-
-